List of Excipients in Branded Drug GLOFIL-125

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Iso-Tex Diagnostics Inc	GLOFIL-125	sodium iothalamate i-125 injection	50914-7729	BENZYL ALCOHOL
Iso-Tex Diagnostics Inc	GLOFIL-125	sodium iothalamate i-125 injection	50914-7729	HYDROCHLORIC ACID
Iso-Tex Diagnostics Inc	GLOFIL-125	sodium iothalamate i-125 injection	50914-7729	SODIUM BICARBONATE

GLOFIL-125 Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

GLOFIL-125 is a sodium iodohippurate I-125 diagnostic radiopharmaceutical used to measure effective renal plasma flow and support renal function evaluation. Its commercial opportunity is unlikely to depend on a conventional excipient patent. The stronger opportunities are dose stability, radiolysis control, low-sorption packaging, extended distribution, ready-to-use presentation, and integration with nuclear medicine workflow.

What is GLOFIL-125 and how does its formulation create commercial value?

GLOFIL-125 contains sodium iodohippurate labeled with iodine-125. The product is administered intravenously and cleared by the kidneys, allowing renal plasma flow to be estimated from blood and urine measurements. Iodine-125 has a physical half-life of approximately 59.4 days, which creates a logistics advantage over short-lived radionuclides but also imposes long-term radiochemical stability requirements. (U.S. Nuclear Regulatory Commission, 2024)

The formulation must preserve:

• Chemical identity of sodium iodohippurate.
• Radiochemical purity of the iodine-125 label.
• Sterility and bacterial endotoxin control.
• Isotonicity and acceptable intravenous tolerability.
• Accurate activity measurement throughout the labeled shelf life.
• Low adsorption to the primary container and dose-delivery components.
• Consistent renal clearance behavior.

The commercial product is a specialized diagnostic agent rather than a mass-market pharmaceutical. The addressable market is therefore driven by nuclear medicine centers, nephrology programs, clinical research sites, and hospitals that perform quantitative renal function studies.

What excipients are most relevant to GLOFIL-125?

The core excipient strategy should remain minimal. A conventional parenteral vehicle based on sterile water and sodium chloride, with pH adjustment or buffering where necessary, is more commercially defensible than a complex formulation.

Public product information for sodium iodohippurate I-125 injection identifies an aqueous injectable presentation. Exact excipient composition, concentration, pH range, preservative status, and container closure configuration must be taken from the current manufacturer’s labeling and chemistry, manufacturing, and controls documentation. The strategic assessment below applies to the formulation requirements of an I-125 sodium iodohippurate injection and does not assume that every listed excipient is present in the marketed product. (DailyMed, n.d.)

Sodium chloride

Sodium chloride is the most commercially practical tonicity agent. It is familiar to regulators, compatible with intravenous administration, inexpensive, and easy to source under pharmaceutical quality systems.

A sodium chloride-based formulation has several advantages:

• Low formulation complexity.
• Low risk of unexpected pharmacokinetic effects.
• Straightforward sterile manufacturing.
• Simple comparability against the existing product.
• Low probability of an excipient-driven safety objection.

The principal risks are precipitation or instability caused by pH shifts, interaction with container surfaces, and changes in osmolality during concentration or activity adjustments.

Phosphate or other buffers

A low-capacity phosphate buffer may be useful if pH drifts during storage or radiolysis. Buffer selection requires caution because the formulation is a radiolabeled injectable and must remain chemically simple.

Potential problems include:

• Precipitation with metal contaminants.
• Changes in ionic strength.
• Increased analytical complexity.
• Possible impact on labeling chemistry.
• Greater difficulty demonstrating equivalence to the reference product.

A buffer should be used only when stability data show that unbuffered saline does not maintain the required pH and radiochemical profile.

Hydrochloric acid and sodium hydroxide

Dilute hydrochloric acid or sodium hydroxide can be used for pH adjustment. These materials are unlikely to create meaningful composition-of-matter exclusivity, but they can support a robust manufacturing process by controlling the final pH range.

The process should define:

• Addition sequence.
• Maximum adjustment volume.
• Mixing conditions.
• In-process pH acceptance criteria.
• Impact of pH adjustment on radiochemical purity.
• Hold time before filling.

Antioxidants and radiolysis inhibitors

Radiolysis is a central formulation issue for iodine-125 products. Ionizing radiation can generate reactive species that affect the organic iodohippurate molecule, the label, or the container system.

Potential stabilizers include antioxidants or radical scavengers, but each creates regulatory and commercial tradeoffs. An antioxidant may:

• Improve radiochemical stability.
• Reduce radiolytic degradation products.
• Extend usable shelf life.
• Complicate toxicological qualification.
• Affect iodine-125 labeling chemistry.
• Introduce extractables, impurities, or compatibility risks.

A stabilizer should not be selected solely because it improves a forced-degradation profile. It must demonstrate benefit under real-time storage, shipment, dose withdrawal, and end-of-shelf-life conditions.

Chelating agents

Chelators such as edetate derivatives can reduce trace-metal catalyzed degradation in some injectable formulations. Their use in GLOFIL-125 would require a clear mechanistic justification and compatibility evidence.

Potential concerns include:

• Interaction with trace metals in manufacturing equipment.
• Changes in radiolabel stability.
• New impurity profiles.
• Increased formulation complexity.
• Limited commercial differentiation.

A chelator is more attractive if trace-metal analysis demonstrates a repeatable correlation between metal burden and radiochemical degradation.

Preservatives

A preservative-free, single-dose presentation is the preferred strategy. Preservatives such as benzyl alcohol, phenol, or parabens could create unnecessary concerns for an intravenous diagnostic radiopharmaceutical.

A preservative-free product supports:

• Simpler toxicology.
• Better pediatric and vulnerable-patient positioning.
• Reduced excipient sensitivity concerns.
• Cleaner regulatory comparability.
• Single-use dose packaging.

Multidose presentations may reduce packaging cost, but they introduce repeated-entry, antimicrobial-effectiveness, and sterility risks. The low volume and specialized use of GLOFIL-125 generally favor single-dose packaging.

What formulation patents could protect an improved GLOFIL-125 product?

A patent directed only to sodium chloride, water, and routine pH adjustment would likely have limited strength. Conventional excipients and standard sterile injectable techniques are vulnerable to prior-art and obviousness challenges.

More defensible patent positions could focus on a defined combination of:

• Sodium iodohippurate I-125.
• A specific antioxidant or radical scavenger.
• A defined pH range.
• A measured radiochemical purity threshold.
• A defined end-of-shelf-life impurity profile.
• A low-sorption container closure.
• A stability period materially longer than the reference product.
• A dose-calibration or dispensing configuration.

A formulation patent should link composition to a measurable technical result. Useful claim-supporting endpoints include:

Technical result	Commercial relevance
Higher radiochemical purity at expiration	Fewer rejected doses
Lower free iodide formation	More reliable quantitative studies
Reduced adsorption to vial or syringe	Improved dose accuracy
Longer usable shelf life	Lower inventory waste
Lower radiolysis after transport	Wider distribution radius
Consistent activity concentration	Better dose preparation and billing

The strongest intellectual-property strategy may combine formulation claims with packaging, manufacturing, and use claims. A conventional excipient mixture alone is less likely to create a durable barrier.

How should the primary container and excipient system be designed?

Container compatibility may create more value than the excipient selection. Iodinated radiopharmaceuticals can experience adsorption, leachables, label instability, and dose-concentration changes during storage.

Preferred packaging strategy

A practical commercial configuration would include:

• Type I glass vial or validated low-sorption polymer container.
• Fluoropolymer-coated or otherwise compatible elastomer closure.
• Single-dose presentation.
• Shielded secondary packaging.
• Clearly defined maximum withdrawal time.
• Calibrated activity at a specified reference date and time.
• Low-dead-volume syringe or transfer device where feasible.

The product should be tested in the final marketed container, not only in laboratory glassware. Studies should cover upright and inverted storage, repeated puncture if relevant, shipping vibration, temperature excursions, radiation exposure, and end-of-shelf-life withdrawal.

Excipient and container interaction

An antioxidant may reduce radiolysis but also change the interaction between the solution and the closure. Conversely, a low-sorption closure may eliminate the need for a formulation stabilizer. This creates a cost and regulatory tradeoff:

Strategy	Benefit	Main risk
Add antioxidant	May improve radiochemical stability	New toxicology and impurity burden
Use low-sorption closure	Improves dose recovery	Higher component cost
Increase buffer capacity	Controls pH drift	More complex composition
Use preservative-free vial	Cleaner regulatory profile	Requires strict single-use control
Use polymer container	Lower breakage risk	Extractables and adsorption
Use glass vial	Established parenteral platform	Potential surface interaction

What FDA regulatory pathway applies to GLOFIL-125 improvements?

GLOFIL-125 is regulated as a prescription diagnostic radiopharmaceutical. A reformulated product would generally require an FDA submission that addresses the change in composition, manufacturing process, container closure, stability, sterility, radiochemical purity, and clinical or bridging implications, depending on the scope of the change. FDA’s radiopharmaceutical guidance emphasizes product quality, dose accuracy, radionuclidic identity, radiochemical purity, sterility, and controls over radioactive materials. (U.S. Food and Drug Administration, 2019)

The regulatory burden depends on the change:

Change	Likely regulatory significance
Minor pH adjustment within established range	Potentially moderate CMC change
New buffer	Requires compatibility and stability justification
New antioxidant	Higher CMC and safety burden
New container closure	Extractables, leachables, adsorption, and stability data
New dosage concentration	Dose uniformity and clinical comparability issues
Extended shelf life	Full real-time and accelerated stability package
Ready-to-use prefilled syringe	Device, sterility, dose accuracy, and container data
Multidose presentation	Antimicrobial and repeated-use controls

The preferred development path is a minimal-change formulation that improves stability without changing the administered amount of sodium iodohippurate or the clinical interpretation of the renal clearance measurement.

What commercial opportunities exist for an improved GLOFIL-125 presentation?

Extended shelf life and wider distribution

Iodine-125’s 59.4-day half-life supports regional distribution and inventory planning. An improved formulation could reduce degradation-related waste and allow centralized production with shipment to more nuclear medicine sites.

Commercial value would come from:

• Fewer discarded vials.
• Lower emergency replacement shipments.
• More predictable hospital inventory.
• Expanded coverage of smaller renal medicine programs.
• Better utilization of centralized radiopharmacy capacity.

Ready-to-use dosing

A ready-to-use vial or prefilled syringe could reduce dose-preparation work and operator exposure. The product must maintain dose accuracy despite radioactive decay and must provide a clear activity reference time.

The highest-value features are:

• Factory-calibrated activity.
• Barcode-enabled dose identification.
• Low residual volume.
• Shielded delivery.
• Simple withdrawal procedure.
• Clear expiration and calibration-time labeling.

Reduced operator exposure

The commercial proposition is stronger if the formulation is paired with a delivery system that reduces manipulation. A prefilled or partially shielded system may command a premium if it lowers preparation time and radiation exposure while preserving dose accuracy.

Contract manufacturing and private-label supply

Because the market is specialized, contract manufacturing can be attractive. A manufacturer with validated radioiodination, aseptic filling, shielding, and radioactive-material logistics could supply:

• Hospital systems.
• Regional radiopharmacies.
• Clinical trial sponsors.
• Specialty diagnostic distributors.
• International licensees.

The principal barrier is not the excipient cost. It is the infrastructure required for radionuclide procurement, validated production, release testing, transportation, and regulatory compliance.

Research-use and clinical-trial supply

A standardized sodium iodohippurate I-125 product could support renal-function studies in drug development. Sponsors evaluating nephrotoxicity, renal clearance, or transporter effects may value consistent, documented supply.

This segment requires strict control of:

• Specific activity.
• Radiochemical purity.
• Dose calibration.
• Lot-to-lot consistency.
• Sample collection protocols.
• Stability during the study period.

How strong is the patent estate for an excipient-based GLOFIL-125 product?

The likely patent strength is moderate to weak for basic excipient claims and stronger for integrated formulation-packaging systems that produce a documented stability or dose-accuracy advantage.

Patent subject	Expected strength
Saline vehicle alone	Weak
Routine pH adjustment	Weak
Conventional buffer	Weak to moderate
Specific radiolysis inhibitor with demonstrated effect	Moderate
Excipient-container combination reducing adsorption	Moderate
Extended-shelf-life formulation	Moderate to strong if technically demonstrated
Prefilled radiopharmaceutical delivery system	Moderate
Manufacturing process with defined impurity control	Moderate
Method of measuring renal plasma flow	Potentially constrained by prior art and use history

Freedom-to-operate analysis should cover active patents, expired patents, abandoned applications, regulatory exclusivity, and third-party container or delivery-system rights. A conventional formulation may have limited patent risk but also limited exclusivity.

What generic entry risks exist for GLOFIL-125?

Generic or follow-on entry risk is shaped by manufacturing capability rather than by conventional pharmaceutical scale economics. A competing product would need access to iodine-125, validated iodohippurate synthesis and labeling, aseptic radioactive filling, suitable shielding, release testing, and compliant distribution.

The principal entry scenarios are:

1. A direct injectable competitor with the same active radiolabeled ingredient.
2. A product with a different concentration or presentation.
3. A hospital-compounded or radiopharmacy-prepared alternative.
4. A competing renal-function tracer using another radionuclide.
5. A nonradioactive or imaging-based renal assessment method.

Excipient patents are unlikely to block all of these routes. The most durable commercial barriers are supply contracts, validated manufacturing capacity, physician familiarity, clinical workflow integration, and reliable distribution.

How does GLOFIL-125 compare with competing renal-function agents?

GLOFIL-125 competes with other methods used to assess renal function and renal plasma flow, including technetium-99m agents, iodine-131 hippuran products where available, endogenous-marker testing, and imaging-based methods.

Attribute	GLOFIL-125	Technetium-99m renal agents	Conventional serum markers
Measurement type	Quantitative tracer clearance	Imaging and functional assessment	Indirect renal function
Radionuclide half-life	Approximately 59.4 days	Approximately 6 hours for Tc-99m	Not applicable
Distribution	Regional or centralized supply feasible	Requires short-cycle radiopharmacy logistics	Broad
Radiation handling	Required	Required	Not required
Excipient opportunity	Stability and adsorption control	Kit reconstitution and labeling stability	Limited
Main commercial constraint	Specialized workflow	Radionuclide availability and scheduling	Lower specificity for some applications

GLOFIL-125’s long physical half-life is useful for supply planning, but the product remains dependent on specialized testing protocols. A commercial upgrade should focus on reducing operational friction rather than adding nonessential excipients.

What licensing and partnership opportunities are available?

Potential transactions include:

• Licensing an improved stabilized formulation.
• Co-development with a radiopharmacy network.
• Exclusive regional distribution.
• Contract manufacturing with a nuclear medicine supplier.
• Packaging or device licensing for shielded dose delivery.
• Clinical-trial supply agreements.
• Hospital-system purchasing arrangements.

The most financeable package would combine a validated formulation, a container-closure system, a stability dataset, and a documented operational benefit. A formulation concept without demonstrated end-of-shelf-life performance is unlikely to command significant licensing value.

Key Takeaways

• GLOFIL-125 is a sodium iodohippurate I-125 diagnostic radiopharmaceutical for quantitative renal-function assessment.
• A minimal aqueous formulation using isotonic sodium chloride and controlled pH is the lowest-risk platform.
• Antioxidants, buffers, and chelators should be added only when they solve a documented radiolysis or stability problem.
• Preservative-free single-dose packaging is commercially preferable to a multidose presentation.
• Container compatibility, adsorption control, and dose recovery may create more value than the excipient blend.
• The strongest patent opportunity is an excipient-container-process combination linked to extended shelf life, reduced degradation, or improved dose accuracy.
• Commercial opportunities include ready-to-use dosing, regional distribution, reduced product waste, contract manufacturing, and clinical-trial supply.
• Generic entry risk is constrained primarily by radioactive-material supply, specialized manufacturing, release testing, and distribution infrastructure.
• The preferred development strategy is a minimal-change formulation with a measurable stability and workflow advantage.

FAQs

Can GLOFIL-125 be reformulated with an antioxidant?

Yes, but the antioxidant must demonstrate a meaningful reduction in radiolysis or radiochemical degradation without compromising labeling chemistry, sterility, intravenous tolerability, or container compatibility.

Is a preservative necessary for GLOFIL-125?

A preservative is generally unattractive for a specialized intravenous radiopharmaceutical. A single-dose, preservative-free presentation is usually the cleaner commercial and regulatory design.

Can a new excipient formulation receive patent protection?

Potentially, but routine saline, buffering, or pH-adjustment claims are weak. Protection is stronger when the formulation produces a measured improvement in radiochemical purity, shelf life, dose recovery, or container compatibility.

Does iodine-125 allow long-distance distribution of GLOFIL-125?

Yes. Its approximately 59.4-day physical half-life supports longer distribution windows than short-lived radionuclides. Chemical and radiochemical stability still determine the practical shelf life.

What is the highest-value product improvement for GLOFIL-125?

The highest-value improvement is likely a ready-to-use, low-sorption, preservative-free presentation with validated end-of-shelf-life radiochemical purity and accurate dose withdrawal.

References

DailyMed. (n.d.). Sodium iodohippurate I-125 injection product information. U.S. National Library of Medicine.

U.S. Food and Drug Administration. (2019). PET drugs: Current good manufacturing practice (CGMP); small entity compliance guide. U.S. Department of Health and Human Services.

U.S. Nuclear Regulatory Commission. (2024). Radiopharmaceuticals and radioactive material regulations. U.S. Government Publishing Office.

U.S. Pharmacopeia. (2023). General chapter <823>: Positron emission tomography drugs for compounding, investigational, and research uses. United States Pharmacopeial Convention.